DOCSLIB.ORG

Scientific Review on the Link Between the Narcotic Effects of Solvents and (Developmental) Neurotoxicity Final Report Prepared F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scientific Review on the Link Between the Narcotic Effects of Solvents and (Developmental) Neurotoxicity Final Report Prepared F Scientific review on the link between the narcotic effects of solvents and (developmental) neurotoxicity Final report Prepared for ECHA Contract Number : ECA.6677-E3 DMG de Groot Cerespark 1, 5844AE Stevensbeek, NL March 2017 Scientific Review (Final Report, R1): OECD TG 443, Organic Solvents, DNT triggers 14 March 2017 Scientific review on the link between the narcotic effects of solvents and (developmental) neurotoxicity Contract Number: ECA.6677-E3 March 2017 Final Report Prepared for the European Chemicals Agency (ECHA) by DMG de Groot PhD, ERT Cerespark 1, 5844AE Stevensbeek, NL Tel: +31 644 163 121 Email: [email protected] Document Change Record Report Version Date Change details Outline 31 Augustus 2016 Draft Final report V1 30 September 2016 Prepared in light of ECHA comments discussed (by teleconference) 25-08-2016; 09-09-2016 Draft Final report R1 02 October 2016 Finetuning (referenceslist; tables) Draft Final report R2 25 October 2016 Revised in light of (written) ECHA comments Draft Final report R3 22 November 2016 Revised in light of ECHA comments discussed (by teleconference) 10-11-2016 Final report V1 09 January 2017 Completed in light of (written) ECHA comments Final report R1 14 March 2017 Finetuning (executive summary; chapter numbering) in light of ECHA comments discussed (by teleconference) 02-03-2017 Disclaimer The views and propositions expressed herein are, unless otherwise stated, those of DMG de Groot and do not necessarily represent any official view of ECHA. DMG de Groot PhD, ERT i Scientific Review (Final Report, R1): OECD TG 443, Organic Solvents, DNT triggers 14 March 2017 Table of Contents Document Change Record ..…………………………………………………………………………………………..…………..….….. i Disclaimer ..…………………………………………………………………………………………..…………………………………..….….. i Table of Contents ………………………………………………………………………………………..………………………………...... ii Glossary ………………………………………………………………………………………………………………………..…………..….… vi Executive summary …………………………………………………………………………………………………..…………………... viii 1 INTRODUCTION .................................................................................................................. 1 1.1 Introduction .............................................................................................................................. 1 1.2 Organic solvents ................................................................................................................ 2 1.2.1 How are organic solvents defined in this review? …………………………………………………………….…… 2 1.2.2 Solvent properties: volatility, lipophilicity and small molecule size …………………..…………..……… 3 1.2.3 Narcotic effects of organic solvents …………………………………………………….…………..….………...….… 3 1.2.4 How are ‘narcosis’, ‘anesthesia’ and ‘narcotic organic solvents’ defined in this review?.......... 4 1.2.5 On the mechanism(s) of narcotic/neurologic effects of narcotic organic solvents ….…….....…… 5 1.2.6 Solvents: usage and exposure ………………………………………………………………………………….………..… 6 1.3 Narcotic organic solvents and (developmental) neurotoxicity …………………………………...….… 7 1.3.1 Research on Organic Solvents and (developmental) Neurotoxicity ……………………………….…...… 7 2 METHODS ………………………………………………………………………………………………………………..……. 10 2.1 Selection, grouping and evaluation of narcotic organic solvents ………………………………..….. 10 2.1.1 Selection of narcotic organic solvents (harmonized classification as STOT SE 3: H336) and developmental neurotoxicity (Annexes 4, 5, 6) …………………………………….…….…..… 10 2.1.2 Grouping of selected narcotic organic solvents classified as STOT SE 3: H336 (Annex 7) …………………………………………………………………………………………………………….….… 10 3 RESULTS ……………………………………………………………………………………………………..…………….…… 12 3.1 Presentation of grouping, narcosis and neurotoxicity of selected narcotic organic solvents ………………………………………..………………………………………………………………....… 12 3.1.1 Narcotic effects and/or (developmental) neurotoxicity of selected and grouped narcotic organic solvents (harmonized classification as STOT SE 3: H336) (Table 1) ………………...….…... 12 3.2 Evaluation of grouping, narcosis and neurotoxicity of selected narcotic organic solvents …..…………………………………………………………………………………………………….….. 15 3.2.1 Narcosis and/or neurotoxicity of selected organic solvents: main grouping (Table 1) ….…..… 15 DMG de Groot PhD, ERT ii Scientific Review (Final Report, R1): OECD TG 443, Organic Solvents, DNT triggers 14 March 2017 3.2.2 Neurologic effects of the organic solvents presented in Table 1: individual results ………....…. 15 3.2.3 Summary / Conclusions on grouping of the narcotic organic solvents, the narcosis and neurotoxicity …………………………………………………………………………………………....…… 17 4. DISCUSSION ……………………………………………………………………………………………………………....…. 18 4.1 Grouping of the selected solvents based on chemical structure and polarity ……………...…. 18 4.1.1 Narcosis and neurotoxicity of grouped organic solvents based on chemical structure .…….... 18 4.1.2 Narcosis and neurotoxicity of grouped organic solvents: polarity ranking …………………….…… 18 4.2 Evaluation of potential target molecules for narcosis and/or neurotoxicity ………………..…. 19 4.2.1 Narcotic/neurologic effects following acute exposure to organic solvents …………………..…..… 19 4.2.2 Narcotic/neurologic effects following sub-chronic /chronic (low-level) exposure to organic solvents ………………………………………………………………………………………………….…..….….19 4.2.3.1 Excitatory ion channel receptors: NMDA-glutamate receptor ……………………………………..…….. 20 4.2.3.2 Toluene exposure and NMDA-glutamate receptor …………………………………………………..….……… 20 4.2.4.1 Inhibitory ion channel receptors: GABA receptor ………………………………………………………..……… 21 4.2.4.2 Toluene, Propofol, and GABA receptor ………………………………………………………………………….….… 21 4.2.5 Unique behavior of GABAA (NMDA and AMPA) during nervous system development …………. 22 4.2.6 Dopamine and suspected organic solvent-induced neurodegenerative diseases ……….…..…… 23 5. REFERENCES …………………………………………………………………………………………………………………… 25 ANNEX 1 ………………………………………………………………………………………………………………………………...… 43 A1 Solvents: usage and exposure ……………………………………………………………………………….……… 43 ANNEX 2………………………………………………………………………………………………………………………..……….…. 44 A 2 Development of the nervous system ……………………………………………………………………….…..… 44 A2.1 Stem cells, neurons and glial cells …………………………………………………………………………..…………. 44 A2.2 Neurotrophic factors …………………………………………………………………………………..…………………….. 45 A2.3 Stages of brain development ………………………………………………………………………………………….……45 A2.4 Duration and completion of the different developmental processes ………………………….….…… 46 A2.5 Outgrowth of dendrites and axons …………………………………………………………………….………….….. 47 A2.6 Apoptosis / Synapse pruning ……………………………………………………………………………………….…..… 47 ANNEX 3 …………………………………………………………………………………………………………………………………… 48 A3 Considerations for grouping organic solvents for narcosis and neurotoxicity …….…….….… 48 DMG de Groot PhD, ERT iii Scientific Review (Final Report, R1): OECD TG 443, Organic Solvents, DNT triggers 14 March 2017 A3.1 Chemical structure and physical-chemical properties …………………………………………………….. 48 A3.1.1 Substance with strong electrophilic character …………………………………………………………..…….…. 48 A3.1.2 Toxic metabolite ……………………………………………………………………………………………………….…….…. 48 A3.1.3 D-structure of the molecule …………………………………………………………………………………………….…. 49 A3.1.4 The reporting by different sources on the physical-chemical properties of a substance ……… 49 A3.2 Grouping of solvents based on physical-chemical properties …………………………………………. 49 A3.2.1 Example from the literature (McKee et al., 2015) ………………………………………………………………. 49 Blanc page …………………………………………………………………………….……………………………………………………….. 51 ANNEX 4 ……………………………………………………………………………………………………………………………...……. 52 A4.1 Substances registered under REACH with harmonised classification as STOT SE 3: H336 ... 52 A4.1.1 References to Annexes 4, 5, 6 …………………………..………………………………………………………..…..…. 53 A4.1.2 Table with selection of narcotic organic solvents (taken from ECHA dissemination site) ….… 59 ANNEX 5 …………………………………………………………………………………………………………………………….……… 97 A5.1 Articles, reports and other documents searched and studied for this review ……………..….. 97 A5.1.1 Table with Articles, reports and documents (complete references included) ………………………. 98 Blanc page …………………………………………………………………………….…………………………………………………….. 136 ANNEX 6…………………………………………………………………………………………………………………………………… 137 A6.1 Information on developmental neurotoxicity derived from Annexes 4 and 5 ………..…..… 137 A6.1.1 Information on developmental neurotoxicity, derived from Annex 4 ……………………..…..…… 138 A6.1.2 Information on developmental neurotoxicity, derived from Annex 5 …………………….……….… 143 Blanc page …………………………………………………………………………….…………………………………………………….. 174 ANNEX 7 ………………………………………………………………………………………………………………………………….. 175 A7.1 Detailed information on grouping of selected narcotic organic solvents ………..…………….. 175 A7.1.1 Abbreviations to Annex 7 ………………………………………………………………………………..…………..…… 176 DMG de Groot PhD, ERT iv Scientific Review (Final Report, R1): OECD TG 443, Organic Solvents, DNT triggers 14 March 2017 A7.1.2 Table with detailed information on grouping of selected narcotic organic solvents …….…... 177 Blanc page …………………………………………………………………………….…………………………………………………….. 226 ANNEX 8 ………………………………………………………………………………………………………………………………..… 227 A8 Organic solvents and ion channel receptors ……………………………………………………………….… 227 A8.1 Excitatory ion channel receptors ………………………………………………………………………….….…… 227 A8.1.1 NMDA-glutamate receptor ………………………………………………………………………………….…………… 227 A8.2 Inhibitory ion channel receptors ………………………………………………..………………………………… 227 A8.2.1 Gamma aminobutyric acid-A (GABAA ) ………………………………………….……………………..………..…
Load more

Recommended publications
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • SUMMARY of an INVESTIGATION of the COMPOSITION of a MIDCONTINENT PETROLEUM DISTILLATE, BOILING BETWEEN 100° and 130° C.L
    U. S. DEPARTMENT OF COMMERCE NATIONAL BUREAU OF STANDARDS RESEARCH PAPER RP1174 Part of Journal of Research of the National Bureau of Standards, Volume 22, February 1939 SUMMARY OF AN INVESTIGATION OF THE COMPOSITION OF A MIDCONTINENT PETROLEUM DISTILLATE, BOILING BETWEEN 100° AND 130° C.l By Robert T. Leslie 2 ABSTRACT The results of 7 years of investigation of the composition of the naphtha fraction of petroleum boiling between 1000 and 1300 C are summarized. Of the 130 liters found to boil in this range after the first laboratory distillation, the constitu­ ents of about one-sixth of the volume were identified or characterized by physical properties, isolated or concentrated, and their concentration in the petroleum roughly estimated. About one-fourth of the volume remains as unidentified distillate. This is composed in part of material of which the constitution is only predicted (about one-twelfth of the volume) and of additional quantities of the constituents which were isolated previously (about one-sixth of the volume). The remainder was lost during the investigation or distilled out of the range on subsequent distillations. Photomicrographic studies were made of those con­ centrations of distillate which could be crystallized. There is given a bibliography of the physical constant s of hydrocarbons reported to boil within this range. CONTENTS Page I. Introduction __ __ ________ __ ____ ______ ________________________ ____ 153 II. Study of the composition of the distillate ___ ___________ __ ___ ________ 164 1. Distillate between 98 0 and 102 0 C ___ _________ ________________ 164 2. Distillate between 1030 and 106 0 C _ _ _ _ __ __ __ __ __ _ __ _ _ _ __ __ _ __ 164 3.
    [Show full text]
  • Toluene Poisoning (Accidental Ingestion of Evostik) Summary
    Toluene Poisoning (Accidental Ingestion of Evostik) *Solarin A.U1, Aremu E.O1, Gbelee O.H1, Animasahun A.B1, Akinola A.O1, Ogunlana A.T1, Nwakpele O.T1, Olugbade O1 1. Department of Paediatrics, Lagos State University Teaching Hospital, Ikeja Lagos. Corresponding Author: Solarin A.U. Email address: [email protected] Summary INTRODUCTION Childhood poisoning is one of the causes of high morbidity and mortality especially among under-five children in low income countries. The home and its surroundings may harbour poisonous substances which might be ingested by adventurous children. Evo-stik glue is a modified silane (MS) polymer based high performance adhesive. It contains toluene, a colourless, sweet-smelling liquid with detrimental effects on virtually every organ in the body especially brain and kidneys. Toluene is a component of household items such as gasoline, shoe and nail polish. AIM / OBJECTIVES From a few reported cases of toluene poisoning worldwide there was need to create awareness on the possibility of toluene poisoning as well as its deleterious effects. This is a case report on exposure to the effects of toluene by accidental ingestion that set the platform to emphasize the importance of prompt and appropriate management of toluene poisoning. METHODOLOGY This case report is about a 2year old girl who accidentally ingested 15-20ml evostik glue stored in an attractive container in the home. QH was presented at the Lagos State University Teaching Hospital Paediatric Emergency Unit with a one day history of persistent spontaneous, non-projectile and non-bilous vomiting. On admission, she was conscious, moderately dehydrated with dry buccal mucosa.
    [Show full text]
  • Directive Effects in Abstraction Reactions of the Phenyl Radical Robert Frederick Bridger Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1963 Directive effects in abstraction reactions of the phenyl radical Robert Frederick Bridger Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Organic Chemistry Commons Recommended Citation Bridger, Robert Frederick, "Directive effects in abstraction reactions of the phenyl radical " (1963). Retrospective Theses and Dissertations. 2336. https://lib.dr.iastate.edu/rtd/2336 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. This dissertation has been 63-5170 microfilmed exactly as received BRIDGER, Robert Frederick, 1934- DIRECTIVE EFFECTS IN ABSTRACTION RE­ ACTIONS OF THE PHENYL RADICAL. Iowa State University of Science and Technology Ph.D., 1963 Chemistry, organic University Microfilms, Inc., Ann Arbor, Michigan DIRECTIVE EFFECTS IN ABSTRACTION REACTIONS OF THE PHENYL RADICAL by Robert Frederick Bridger A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OF PHILOSOPHY Major Subject: Organic Chemistry Approved: Signature was redacted for privacy. In Charge of Major Work Signature was redacted for privacy. Head of Major Depart me6jb Signature was redacted for privacy. Iowa State University Of Science and Technology Ames, Iowa 1963 ii TABLE OF CONTENTS Page INTRODUCTION 1 LITERATURE REVIEW 3 RESULTS 6 DISCUSSION 36 EXPERIMENTAL 100 SUMMARY 149 REFERENCES CITED 151 ACKNOWLEDGEMENTS 158 iii LIST OF FIGURES Page Figure 1.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • WO 2015/095882 Al 25 June 2015 (25.06.2015) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/095882 Al 25 June 2015 (25.06.2015) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.0 1) C12Q 1/70 (2006.0 1) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 14/07 1963 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 22 December 2014 (22. 12.2014) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/ 19,663 20 December 201 3 (20. 12.20 13) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: THE REGENTS OF THE UNIVERSITY GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, OF CALIFORNIA [US/US]; 1111 Franklin Street, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Twelfth Floor, Oakland, CA 94607-5200 (US).
    [Show full text]
  • Safe Injection Practices for Administration of Propofol
    Safe Injection Practices for Administration of Propofol CECIL A. KING, MS, RN; MARY OGG, MSN, RN, CNOR ABSTRACT Sepsis and postoperative infection can occur as a result of unsafe practices in the administration of propofol and other injectable medications. Investigations of infec- tion outbreaks have revealed the causes to be related to bacterial growth in or contamination of propofol and unsafe medication practices, including reuse of syringes on multiple patients, use of single-use medication vials for multiple pa- tients, and failure to practice aseptic technique and adhere to infection control practices. Surveys conducted by AORN and other researchers have provided addi- tional information on perioperative practices related to injectable medications. In 2009, the US Food and Drug Administration and the Centers for Disease Control and Prevention convened a group of clinicians to gain a better understanding of the issues related to infection outbreaks and injectable medications. The meeting participants proposed collecting data to persuade clinicians to adopt new practices, developing guiding principles for propofol use, and describing propofol-specific, site-specific, and practitioner-specific injection techniques. AORN provides resources to help perioperative nurses reduce the incidence of postoperative infection related to med- ication administration. AORN J 95 (March 2012) 365-372. © AORN, Inc, 2012. doi: 10.1016/j.aorn.2011.06.009 Key words: sterile injectable medications, propofol, sepsis, safe injection prac- tices, safe medication
    [Show full text]
  • EARTH Title Description ENTITIES ATTRIBUTES DYNAMIC ASPECTS
    EARTH Title Description ENTITIES ATTRIBUTES DYNAMIC ASPECTS DIMENSIONS ACCESSORY TERMS <EFFECTS AND SINGLE EVENTS> <STRUCTURE AND MORPHOLOGY> ACTIVITIES COMPOSITION CONDITIONS GENERAL TERMS IMMATERIAL ENTITIES MATERIAL ENTITIES PROCESSES PROPERTIES TIME <ABIOTIC ENVIRONMENT PROCESSES> <BIOECOLOGICAL PROCESSES> <COGNITIVE PROCESSES> <COMPLEX> <MENTAL CONSTRUCTS> <PHYSICAL AND CHEMICAL PROCESSES> <PHYSICAL OPERATIONS> <POLICY ACTIVITIES> <PROCESSES OF COMPLEX SYSTEMS (BY GENERAL TYPE)> <PROCESSES RELATED TO MATERIALS AND PRODUCTS> <PRODUCTIVE SECTORS> <SOCIAL AND CULTURAL ACTIVITIES> <SOCIAL, CULTURAL AND POLICY PROCESSES> INDUSTRY LIVING ENTITIES NON LIVING ENTITIES <ABSTRACT CONCEPTS AND PRINCIPLES> <DISPOSAL AND RESTORATION> <KNOWLEDGE SYSTEMS> <MANIPULATION, PRODUCTION, CONSUMPTION> <MEASURES> <METHODS AND TECHNIQUES> <PARAMETERS, CRITERIA AND FACTORS> <REPRESENTATION AND ELABORATION SYSTEMS> ARTIFICIAL ENTITIES BIOECOLOGICAL ENTITIES DATA NATURAL ENTITIES NATURAL SPACES BY GENERAL TYPES SOCIAL ENTITIES <ABIOTIC ENVIRONMENT> <BUILT ENVIRONMENT> <EARTH CONSTITUENTS AND MATERIALS> <MATERIALS AND PRODUCTS> <OPEN SPACES, CULTURAL LANDSCAPES> <PARTS> <PHYSICAL AND CHEMICAL CONSTITUENTS> <WHOLE> EQUIPMENT AND TECHNOLOGICAL SYSTEMS symbiotic organisms technological systems <ATMOSPHERE ENVIRONMENT> <ECOSYSTEM ABIOTIC COMPONENTS> <EXTRATERRESTRIAL ENVIRONMENT> <GEOGRAPHICAL REGIONS AND CLIMATIC ZONES> <TERRESTRIAL ENVIRONMENT> <WATER ENVIRONMENT> <CONTINENTAL WATER ENVIRONMENT> <OCEANIC WATER ENVIRONMENT> <TERRESTRIAL AREAS AND LANDFORMS> geological
    [Show full text]
  • Statement on Safe Use of Propofol 2019
    Statement on Safe Use of Propofol Committee of Origin: Ambulatory Surgical Care (Approved by the ASA House of Delegates on October 27, 2004, and amended on October 23, 2019) Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. The Society believes that the involvement of an anesthesiologist in the care of every patient undergoing anesthesia is optimal. However, when this is not possible, non-anesthesia personnel who administer propofol should be qualified to rescue* patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.** • The physician responsible for the use of sedation/anesthesia should have the education and training to manage the potential medical complications of sedation/anesthesia. The physician should be proficient in airway management, have advanced life support skills appropriate for the patient population, and understand the pharmacology of the drugs used. The physician should be physically present throughout the sedation and remain immediately available until the patient is medically discharged from the post procedure recovery area. • The practitioner administering propofol for sedation/anesthesia should, at a minimum, have the education and training to identify and manage the airway and cardiovascular changes which occur in a patient who enters a state of general anesthesia, as well as the ability to assist in the management of complications.
    [Show full text]
  • Landolt-Börnstein Indexes of Organic Compounds Subvolumes A-I by V
    Landolt-Börnstein Indexes of Organic Compounds Subvolumes A-I By V. Vill, C. Bauhofer, G. Peters, H. Sajus, P. Weigner, LCI-Publisher and Chemistry Department of the University of Hamburg All printed index material has been used to build up the comprehensive Scidex database index developed by LCI Publisher GmbH, Hamburg For further information please visit www.lci-publisher.com From this database a CD-ROM and two online versions were derived. The first is attached to each of the printed subvolumes and the latter are offered for free use at the following addresses: Scidex Database online with graphical structure search on http://lb.chemie.uni-hamburg.de/ Or the easy to use html version on http://lb.chemie.uni-hamburg.de/static/ Landolt-Börnstein Numerical Data and Functional Relationships in Science and Technology New Series / Editor in Chief: W. Martienssen Index of Organic Compounds Subvolume A Compounds with 1 to 7 Carbon Atoms Editor: V. Vill Authors: V. Vill, G. Peters, H. Sajus 1 3 ISBN 3-540-66203-0 Springer-Verlag Berlin Heidelberg New York Library of Congress Cataloging in Publication Data Zahlenwerte und Funktionen aus Naturwissenschaften und Technik, Neue Serie Editor in Chief: W. Martienssen Index of Organic Compounds A: Editor: V. Vill At head of title: Landolt-Börnstein. Added t.p.: Numerical data and functional relationships in science and technology. Tables chiefly in English. Intended to supersede the Physikalisch-chemische Tabellen by H. Landolt and R. Börnstein of which the 6th ed. began publication in 1950 under title: Zahlenwerte und Funktionen aus Physik, Chemie, Astronomie, Geophysik und Technik.
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • Toxicological Profile for Toluene
    TOXICOLOGICAL PROFILE FOR TOLUENE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry September 2000 Additional Resources http://www.atsdr.cdc.gov/toxprofiles/tp56.html TOLUENE ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. TOLUENE iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 TOLUENE vi *Legislative Background The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on October 21, 1999 (64 FR 56792). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988(53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); and November 17, 1997 (62 FR 61332).
    [Show full text]